You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAliskiren
Accession NumberDB09026  (DB01258)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAliskiren is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension. While used for high blood pressure, other better studied medications are typically recommended due to concerns of higher side effects and less evidence of benefit. In December 2011, Novartis halted a clinical trial of the drug after discovering increased incidence of nonfatal stroke, kidney complications, high blood potassium, and low blood pressure in people with diabetes and kidney impairment.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet150 mgOralNovartis Pharmaceuticals Canada Inc2007-11-26Not applicableCanada
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet300 mgOralNovartis Pharmaceuticals Canada Inc2007-11-29Not applicableCanada
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated300 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
RasilezTablet, film coated150 mgOralNovartis Europharm Limited2007-08-22Not applicableEu
Sandoz AliskirenTablet300 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz AliskirenTablet150 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
TekturnaTablet, film coated150 mg/1OralNovartis Pharmaceuticals Corporation2007-03-05Not applicableUs
TekturnaTablet, film coated300 mg/1OralA S Medication Solutions2007-03-05Not applicableUs
TekturnaTablet, film coated300 mg/1OralNovartis Pharmaceuticals Corporation2007-03-05Not applicableUs
TekturnaTablet, film coated150 mg/1OralNoden Pharma Usa, Inc.2007-03-05Not applicableUs
TekturnaTablet, film coated150 mg/1OralPhysicians Total Care, Inc.2007-05-23Not applicableUs
TekturnaTablet, film coated300 mg/1OralNoden Pharma Usa, Inc.2007-03-05Not applicableUs
TekturnaTablet, film coated300 mg/1OralPhysicians Total Care, Inc.2009-06-22Not applicableUs
TekturnaTablet, film coated300 mg/1OralA S Medication Solutions2007-03-05Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
AmturnideNovartis Pharmaceuticals Corporation
Rasilez HctNovartis Pharmaceuticals Canada Inc
TekamloNovartis Pharmaceuticals Corporation
Tekturna HctNovartis Pharmaceuticals Corporation
Salts
Name/CASStructureProperties
Aliskiren hemifumarate
ThumbNot applicableDBSALT001203
Categories
UNII502FWN4Q32
CAS number173334-57-1
WeightAverage: 551.7583
Monoisotopic: 551.393436443
Chemical FormulaC30H53N3O6
InChI KeyUXOWGYHJODZGMF-QORCZRPOSA-N
InChI
InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1
IUPAC Name
(2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide
SMILES
COCCCOC1=C(OC)C=CC(C[C@@H](C[[email protected]](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
Pharmacology
IndicationFor the treatment of hypertension, to lower blood pressure.
Structured Indications
PharmacodynamicsIn placebo controlled clinical trials, plasma renin activity (PRA) was decreased in a range of 50% to 80%. This reduction in PRA was not dose‐related and did not correlate with blood pressure reductions. The clinical implications of the differences in effect on PRA are not known.
Mechanism of actionRenin is secreted by the kidney in response to decreases in blood volume and renal perfusion. Renin cleaves angiotensinogen to form the inactive decapeptide angiotensin I (Ang I). Ang I is converted to the active octapeptide angiotensin II (Ang II) by ACE and non‐ACE pathways. Ang II is a powerful vasoconstrictor and leads to the release of catecholamines from the adrenal medulla and prejunctional nerve endings. It also promotes aldosterone secretion and sodium reabsorption. Together, these effects increase blood pressure. Ang II also inhibits renin release, thus providing a negative feedback to the system. This cycle, from renin through angiotensin to aldosterone and its associated negative feedback loop, is known as the renin‐angiotensin‐aldosterone system (RAAS). Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non‐ACE pathways, is not known. All agents that inhibit the RAAS, including renin inhibitors, suppress the negative feedback loop, leading to a compensatory rise in plasma renin concentration. When this rise occurs during treatment with ACEIs and ARBs, the result is increased levels of PRA. During treatment with aliskiren, however, the effect of increased renin levels is blocked so that PRA, Ang I and Ang II are all reduced, whether aliskiren is used as monotherapy or in combination with other antihypertensive agents.
TargetKindPharmacological actionActionsOrganismUniProt ID
ReninProteinyes
inhibitor
HumanP00797 details
Related Articles
AbsorptionPoor, with a bioavailability of about 2.5%.
Volume of distributionNot Available
Protein binding47-51%
Metabolism

Approximately 80% of the drug in plasma following oral administration is unchanged. Cytochrome P450 (CYP) 3A4 oxidation produces two major metabolites that account for approximately 5% of the drug in plasma. Aliskiren is eliminated primarily through the biliary/fecal route as unchanged drug and, to a lesser extent, via oxidative metabolism via CYP3A4. Only 0.6% of the oral dose is recovered in urine.

Route of eliminationAbout one fourth of the absorbed dose appears in the urine as parent drug.
Half lifeApproximate accumulation half‐life of 24 hours.
ClearanceNot Available
ToxicityThe most likely manifestation of overdosage would be hypotension.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Aliskiren.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Aliskiren.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Aliskiren.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Aliskiren is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Aliskiren.Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Aliskiren.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Aliskiren.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Aliskiren.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Aliskiren.Approved, Withdrawn
AmbrisentanAliskiren may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineAliskiren may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Aliskiren.Approved
AmiodaroneThe metabolism of Aliskiren can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Aliskiren.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Aliskiren.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Aliskiren is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Aliskiren.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Aliskiren.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Aliskiren.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Aliskiren.Approved
ApremilastApremilast may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AprepitantThe serum concentration of Aliskiren can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Aliskiren.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Aliskiren.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Aliskiren is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Aliskiren is combined with Arsenic trioxide.Approved, Investigational
AtazanavirThe metabolism of Aliskiren can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Aliskiren.Approved
AtomoxetineThe metabolism of Aliskiren can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Aliskiren can be increased when it is combined with Atorvastatin.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Aliskiren.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Aliskiren.Approved
Azilsartan medoxomilAliskiren may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Aliskiren.Experimental
BarbitalBarbital may increase the hypotensive activities of Aliskiren.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Aliskiren.Approved
BenazeprilAliskiren may increase the hyperkalemic activities of Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Aliskiren.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Aliskiren.Withdrawn
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Aliskiren.Withdrawn
BepridilBepridil may increase the hypotensive activities of Aliskiren.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Aliskiren.Approved
BethanidineBethanidine may increase the hypotensive activities of Aliskiren.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Aliskiren.Investigational
BexaroteneThe serum concentration of Aliskiren can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Aliskiren.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Aliskiren.Approved
BoceprevirThe metabolism of Aliskiren can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Aliskiren can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Aliskiren can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Aliskiren.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Aliskiren.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Aliskiren.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Aliskiren.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Bromocriptine.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Aliskiren.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Aliskiren.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Bupivacaine.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Aliskiren.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Aliskiren.Approved
CandesartanAliskiren may increase the hyperkalemic activities of Candesartan.Approved
CandoxatrilAliskiren may increase the hyperkalemic activities of Candoxatril.Experimental
CaptoprilAliskiren may increase the hyperkalemic activities of Captopril.Approved
CarbamazepineThe metabolism of Aliskiren can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Aliskiren is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Aliskiren.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Aliskiren.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Aliskiren.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Aliskiren.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Aliskiren.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Aliskiren.Approved, Investigational
CeritinibThe serum concentration of Aliskiren can be increased when it is combined with Ceritinib.Approved
CertoparinCertoparin may increase the hyperkalemic activities of Aliskiren.Approved
ChloroquineChloroquine may decrease the antihypertensive activities of Aliskiren.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Aliskiren.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Aliskiren.Approved
CilazaprilAliskiren may increase the hyperkalemic activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Cilnidipine.Approved
ClarithromycinThe metabolism of Aliskiren can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Aliskiren can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Aliskiren.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Aliskiren.Approved
ClonixinClonixin may decrease the antihypertensive activities of Aliskiren.Approved
ClotrimazoleThe metabolism of Aliskiren can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Clozapine.Approved
CobicistatThe metabolism of Aliskiren can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Aliskiren can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Aliskiren can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Aliskiren.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Aliskiren.Investigational
CyclosporineThe serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Aliskiren can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Aliskiren.Approved
D-LimoneneD-Limonene may decrease the antihypertensive activities of Aliskiren.Investigational
DabrafenibThe serum concentration of Aliskiren can be decreased when it is combined with Dabrafenib.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Aliskiren.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Aliskiren.Approved
DarunavirThe metabolism of Aliskiren can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Aliskiren can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Aliskiren.Approved
DeferasiroxThe serum concentration of Aliskiren can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Aliskiren can be decreased when combined with Delavirdine.Approved
DeserpidineAliskiren may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Aliskiren is combined with Desflurane.Approved
DexamethasoneThe serum concentration of Aliskiren can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Aliskiren.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Aliskiren.Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Aliskiren.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Aliskiren.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Aliskiren.Approved
DihydralazineAliskiren may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Aliskiren can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Aliskiren.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Aliskiren is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Aliskiren.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Aliskiren.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Aliskiren.Approved
DoxycyclineThe metabolism of Aliskiren can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Aliskiren can be decreased when combined with Dronedarone.Approved
DrospirenoneDrospirenone may increase the hyperkalemic activities of Aliskiren.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Aliskiren.Approved
DuloxetineAliskiren may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Aliskiren.Investigational
E6201E6201 may decrease the antihypertensive activities of Aliskiren.Investigational
EbselenEbselen may decrease the antihypertensive activities of Aliskiren.Investigational
EfavirenzThe serum concentration of Aliskiren can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineAliskiren may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Aliskiren is combined with Empagliflozin.Approved
EnalaprilAliskiren may increase the hyperkalemic activities of Enalapril.Approved, Vet Approved
EnalaprilatAliskiren may increase the hyperkalemic activities of Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Aliskiren.Approved
EnzalutamideThe serum concentration of Aliskiren can be decreased when it is combined with Enzalutamide.Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Aliskiren.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Aliskiren.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Aliskiren.Approved
EprosartanAliskiren may increase the hyperkalemic activities of Eprosartan.Approved
ErythromycinThe metabolism of Aliskiren can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Aliskiren can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Aliskiren.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aliskiren.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Aliskiren.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
EtravirineThe serum concentration of Aliskiren can be decreased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Aliskiren.Approved
exisulindexisulind may decrease the antihypertensive activities of Aliskiren.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Aliskiren.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Aliskiren.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Aliskiren.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Aliskiren.Approved
FimasartanThe risk or severity of adverse effects can be increased when Aliskiren is combined with Fimasartan.Approved
FloctafenineFloctafenine may decrease the antihypertensive activities of Aliskiren.Approved, Withdrawn
FluconazoleThe metabolism of Aliskiren can be decreased when combined with Fluconazole.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Aliskiren.Vet Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
FluvoxamineThe metabolism of Aliskiren can be decreased when combined with Fluvoxamine.Approved, Investigational
ForasartanAliskiren may increase the hyperkalemic activities of Forasartan.Experimental
FosamprenavirThe metabolism of Aliskiren can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Aliskiren can be increased when it is combined with Fosaprepitant.Approved
FosinoprilAliskiren may increase the hyperkalemic activities of Fosinopril.Approved
FosphenytoinThe metabolism of Aliskiren can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Aliskiren.Approved, Vet Approved
FurosemideThe serum concentration of Furosemide can be decreased when it is combined with Aliskiren.Approved, Vet Approved
Fusidic AcidThe serum concentration of Aliskiren can be increased when it is combined with Fusidic Acid.Approved
GuanabenzGuanabenz may increase the hypotensive activities of Aliskiren.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Aliskiren.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Aliskiren.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Aliskiren.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Aliskiren is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Aliskiren.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Aliskiren.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Aliskiren.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Aliskiren.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Aliskiren.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Aliskiren.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Aliskiren.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Aliskiren.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Aliskiren.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Aliskiren.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Aliskiren.Approved
IdelalisibThe serum concentration of Aliskiren can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Aliskiren.Approved, Investigational
ImatinibThe metabolism of Aliskiren can be decreased when combined with Imatinib.Approved
ImidaprilAliskiren may increase the hyperkalemic activities of Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Aliskiren.Approved
IndenololIndenolol may increase the hypotensive activities of Aliskiren.Withdrawn
IndinavirThe metabolism of Aliskiren can be decreased when combined with Indinavir.Approved
IndomethacinIndomethacin may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Aliskiren.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Aliskiren.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Aliskiren.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Aliskiren.Withdrawn
IrbesartanAliskiren may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Aliskiren can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Aliskiren.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Aliskiren is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Aliskiren.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Aliskiren.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Aliskiren.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Aliskiren.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Aliskiren.Approved
ItraconazoleThe serum concentration of Aliskiren can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Aliskiren can be increased when it is combined with Ivacaftor.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Aliskiren.Experimental
KetanserinAliskiren may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Aliskiren can be decreased when combined with Ketoconazole.Approved, Investigational
KetoconazoleThe serum concentration of Aliskiren can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Aliskiren.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Aliskiren.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Aliskiren.Approved
LacidipineAliskiren may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Aliskiren.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Aliskiren.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Aliskiren.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Levobupivacaine.Approved
LevodopaAliskiren may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Aliskiren is combined with Levosimendan.Approved, Investigational
LisinoprilAliskiren may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Aliskiren.Investigational
LofexidineLofexidine may increase the hypotensive activities of Aliskiren.Approved, Investigational
LopinavirThe metabolism of Aliskiren can be decreased when combined with Lopinavir.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Aliskiren.Approved
LosartanAliskiren may increase the hyperkalemic activities of Losartan.Approved
LovastatinThe metabolism of Aliskiren can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Aliskiren.Approved
LuliconazoleThe serum concentration of Aliskiren can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Aliskiren can be increased when combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
MacitentanAliskiren may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Aliskiren.Approved
ManidipineAliskiren may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Aliskiren.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Aliskiren.Approved
MebanazineMebanazine may increase the hypotensive activities of Aliskiren.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Aliskiren.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Aliskiren.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Aliskiren.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Aliskiren.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Aliskiren.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Aliskiren.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Aliskiren.Approved
MethohexitalMethohexital may increase the hypotensive activities of Aliskiren.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Aliskiren.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Aliskiren.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Aliskiren.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Aliskiren.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Aliskiren.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Aliskiren.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Aliskiren.Approved, Investigational
MetyrosineAliskiren may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Aliskiren.Withdrawn
MifepristoneThe serum concentration of Aliskiren can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Aliskiren.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Aliskiren.Approved
MitotaneThe serum concentration of Aliskiren can be decreased when it is combined with Mitotane.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Aliskiren.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Aliskiren.Approved
ModafinilThe serum concentration of Aliskiren can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilAliskiren may increase the hyperkalemic activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Aliskiren.Approved
MorphineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Morphine.Approved, Investigational
MoxonidineAliskiren may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Aliskiren.Approved
NabiloneThe risk or severity of adverse effects can be increased when Aliskiren is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Aliskiren.Approved
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Aliskiren.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Aliskiren.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Aliskiren.Investigational
NafcillinThe serum concentration of Aliskiren can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the antihypertensive activities of Aliskiren.Approved
NaftopidilAliskiren may increase the hypotensive activities of Naftopidil.Investigational
NaproxenNaproxen may decrease the antihypertensive activities of Aliskiren.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Aliskiren.Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Aliskiren.Approved, Investigational
NefazodoneThe metabolism of Aliskiren can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Aliskiren can be decreased when combined with Nelfinavir.Approved
NepafenacNepafenac may decrease the antihypertensive activities of Aliskiren.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Aliskiren.Approved, Investigational
NetupitantThe serum concentration of Aliskiren can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Aliskiren can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Aliskiren.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Aliskiren.Approved
NicorandilNicorandil may increase the hyperkalemic activities of Aliskiren.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Aliskiren.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Aliskiren.Approved
NiguldipineAliskiren may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Aliskiren can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineNilvadipine may increase the hypotensive activities of Aliskiren.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Aliskiren.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Aliskiren.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Aliskiren.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Aliskiren.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Aliskiren is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Aliskiren.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Aliskiren.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Aliskiren.Approved
ObinutuzumabAliskiren may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Aliskiren.Withdrawn
OlaparibThe metabolism of Aliskiren can be decreased when combined with Olaparib.Approved
OlmesartanAliskiren may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Aliskiren.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Aliskiren.Approved
OmapatrilatAliskiren may increase the hyperkalemic activities of Omapatrilat.Investigational
OrgoteinOrgotein may decrease the antihypertensive activities of Aliskiren.Vet Approved
OsimertinibThe serum concentration of Aliskiren can be increased when it is combined with Osimertinib.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Aliskiren.Approved
OxprenololOxprenolol may increase the hypotensive activities of Aliskiren.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Aliskiren.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Aliskiren is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Aliskiren can be increased when it is combined with Palbociclib.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Aliskiren.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Aliskiren.Approved
PargylinePargyline may increase the hypotensive activities of Aliskiren.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Aliskiren.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Aliskiren.Approved, Investigational
PentobarbitalThe metabolism of Aliskiren can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Aliskiren.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Aliskiren.Approved, Investigational
PerindoprilAliskiren may increase the hyperkalemic activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Aliskiren.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Aliskiren.Withdrawn
PhenobarbitalThe metabolism of Aliskiren can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Aliskiren.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Aliskiren.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Aliskiren.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Aliskiren.Approved, Vet Approved
PhenytoinThe metabolism of Aliskiren can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Aliskiren.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Aliskiren.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Aliskiren is combined with Pipamperone.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Aliskiren.Investigational
PirlindolePirlindole may increase the hypotensive activities of Aliskiren.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Aliskiren.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Aliskiren.Approved
PosaconazoleThe metabolism of Aliskiren can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Aliskiren is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Aliskiren.Approved
PrimidoneThe metabolism of Aliskiren can be increased when combined with Primidone.Approved, Vet Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Aliskiren.Approved
PropofolThe risk or severity of adverse effects can be increased when Aliskiren is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Aliskiren.Approved, Investigational
PTC299PTC299 may decrease the antihypertensive activities of Aliskiren.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Aliskiren.Approved
QuinaprilAliskiren may increase the hyperkalemic activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Aliskiren.Approved
RamiprilAliskiren may increase the hyperkalemic activities of Ramipril.Approved
RanolazineThe metabolism of Aliskiren can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Aliskiren.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Aliskiren is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Aliskiren.Approved
RescinnamineAliskiren may increase the hyperkalemic activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Aliskiren.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Aliskiren.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Aliskiren.Approved
RifabutinThe metabolism of Aliskiren can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Aliskiren can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Aliskiren can be increased when combined with Rifapentine.Approved
RilmenidineAliskiren may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Aliskiren.Approved
RisperidoneAliskiren may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Aliskiren can be decreased when combined with Ritonavir.Approved, Investigational
RituximabAliskiren may increase the hypotensive activities of Rituximab.Approved
RofecoxibRofecoxib may decrease the antihypertensive activities of Aliskiren.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Aliskiren is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Rotigotine.Approved
SacubitrilAliskiren may increase the hyperkalemic activities of Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Aliskiren.Withdrawn
SalicylamideSalicylamide may decrease the antihypertensive activities of Aliskiren.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Aliskiren.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Aliskiren.Approved
SaprisartanAliskiren may increase the hyperkalemic activities of Saprisartan.Experimental
SaquinavirThe metabolism of Aliskiren can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinAliskiren may increase the hyperkalemic activities of Saralasin.Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Aliskiren.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Aliskiren.Approved, Investigational, Vet Approved
SelexipagAliskiren may increase the hypotensive activities of Selexipag.Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Aliskiren is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Aliskiren.Approved, Investigational
SiltuximabThe serum concentration of Aliskiren can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Aliskiren can be increased when it is combined with Simeprevir.Approved
SitaxentanAliskiren may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Aliskiren is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Aliskiren.Approved
SpiraprilAliskiren may increase the hyperkalemic activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Aliskiren.Approved
SRT501SRT501 may decrease the antihypertensive activities of Aliskiren.Investigational
St. John's WortThe serum concentration of Aliskiren can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Aliskiren can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Aliskiren is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Aliskiren is combined with Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Aliskiren.Approved
SulfisoxazoleThe metabolism of Aliskiren can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Aliskiren.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Aliskiren.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Aliskiren.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Aliskiren is combined with Tamsulosin.Approved, Investigational
TasosartanAliskiren may increase the hyperkalemic activities of Tasosartan.Approved
TelaprevirThe metabolism of Aliskiren can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Aliskiren can be decreased when combined with Telithromycin.Approved
TelmisartanAliskiren may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TemocaprilAliskiren may increase the hyperkalemic activities of Temocapril.Experimental, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Aliskiren.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Aliskiren.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Aliskiren.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Aliskiren.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Aliskiren.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Aliskiren is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Aliskiren.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Aliskiren.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Aliskiren is combined with Thioridazine.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Aliskiren.Approved
TiboloneAliskiren may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe metabolism of Aliskiren can be decreased when combined with Ticlopidine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Aliskiren.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Aliskiren.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Aliskiren.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Aliskiren.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Aliskiren.Approved
TocilizumabThe serum concentration of Aliskiren can be decreased when it is combined with Tocilizumab.Approved
TolazolineTolazoline may increase the hypotensive activities of Aliskiren.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Aliskiren is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Aliskiren.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Aliskiren.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Aliskiren.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Aliskiren.Approved
TrandolaprilAliskiren may increase the hyperkalemic activities of Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Aliskiren.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Aliskiren.Approved
TravoprostTravoprost may increase the hypotensive activities of Aliskiren.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Aliskiren.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Aliskiren is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Aliskiren.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Aliskiren.Approved, Vet Approved
TrimazosinAliskiren may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Aliskiren.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Aliskiren.Approved
UdenafilUdenafil may increase the antihypertensive activities of Aliskiren.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Aliskiren.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Aliskiren.Investigational, Withdrawn
ValsartanAliskiren may increase the hyperkalemic activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Aliskiren.Approved
VenlafaxineThe metabolism of Aliskiren can be decreased when combined with Venlafaxine.Approved
VerapamilThe serum concentration of Aliskiren can be increased when it is combined with Verapamil.Approved
VinpocetineAliskiren may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Aliskiren can be decreased when combined with Voriconazole.Approved, Investigational
XylometazolineXylometazoline may increase the hypotensive activities of Aliskiren.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Aliskiren.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Aliskiren.Approved
ZileutonZileuton may decrease the antihypertensive activities of Aliskiren.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Aliskiren can be decreased when combined with Ziprasidone.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Aliskiren.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP: Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47(8):515-31. [PubMed:18611061 ]
  2. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005 Mar 1;111(8):1012-8. Epub 2005 Feb 21. [PubMed:15723979 ]
  3. Staessen JA, Li Y, Richart T: Oral renin inhibitors. Lancet. 2006 Oct 21;368(9545):1449-56. [PubMed:17055947 ]
External Links
ATC CodesC09DX02C09XA02C09XA52C09XA54C09XA53
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (612 KB)
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral150 mg
TabletOral300 mg
Tablet, film coatedOral150 mg
Tablet, film coatedOral300 mg
TabletOral
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2147056 No2005-10-252015-04-13Canada
US5559111 No1998-07-212018-07-21Us
US8168616 No2006-07-032026-07-03Us
US8183295 No2003-05-162023-05-16Us
US8613949 No2009-12-212029-12-21Us
US8617595 No2006-02-192026-02-19Us
US8618172 No2008-07-132028-07-13Us
US8618174 No2001-11-152021-11-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityHighly soluble in water (as hemifumarate salt)Not Available
logP3.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0021 mg/mLALOGPS
logP3.87ALOGPS
logP3.12ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)14.56ChemAxon
pKa (Strongest Basic)9.57ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area146.13 Å2ChemAxon
Rotatable Bond Count19ChemAxon
Refractivity154.32 m3·mol-1ChemAxon
Polarizability64.25 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as delta amino acids and derivatives. These are compounds containing a carboxylic acid group and an amino group at the C5 carbon atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentDelta amino acids and derivatives
Alternative Parents
Substituents
  • Delta amino acid or derivatives
  • Phenylbutylamine
  • Beta amino acid or derivatives
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • N-acyl-amine
  • Fatty amide
  • Monocyclic benzene moiety
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Primary carboxylic acid amide
  • Carboxamide group
  • 1,2-aminoalcohol
  • Ether
  • Dialkyl ether
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Receptor binding
Specific Function:
Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney.
Gene Name:
REN
Uniprot ID:
P00797
Molecular Weight:
45057.125 Da
References
  1. Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002 Jan;39(1):E1-8. [PubMed:11799102 ]
  2. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, Ruger H, Goschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, Schnell CR, Herold P, Mah R, Jensen C, O'Brien E, Stanton A, Bedigian MP: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003 Sep 5;308(4):698-705. [PubMed:12927775 ]
  3. Menard J, Guyene TT, Peyrard S, Azizi M: Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens. 2006 Mar;24(3):529-34. [PubMed:16467656 ]
  4. Azizi M, Webb R, Nussberger J, Hollenberg NK: Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006 Feb;24(2):243-56. [PubMed:16508564 ]
  5. Gradman AH, Vivas Y: New drugs for hypertension: what do they offer? Curr Hypertens Rep. 2006 Oct;8(5):425-32. [PubMed:16965731 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP: Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47(8):515-31. [PubMed:18611061 ]
Comments
comments powered by Disqus
Drug created on October 13, 2014 16:29 / Updated on December 07, 2016 02:39